Disease Overview
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma, accounts for over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive bladder cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.
Market Snapshot
Bladder cancer is the fifth most common cancer in Europe and the ninth most common cancer globally. Symptoms include hematuria, dysuria, increased urinary frequency, and frequent urinary tract infections. Urothelial carcinoma, also known as transitional cell carcinoma, accounts for over 90% of bladder cancers. Approximately three-quarters of urothelial carcinoma patients initially present with non-muscle invasive bladder cancer (NMIBC), which is associated with a relatively good prognosis. However, NMIBCs are characterized by a high risk of recurrence, leading to a high disease burden and making bladder cancer one of the costliest malignancies to treat.
Market Snapshot
- The value of the bladder cancer market is projected to reach $4.8bn by 2025, with growth driven by immunotherapies.
- Pharmacological treatment of urothelial bladder cancer is dominated by platinum-based chemotherapy regimens.
- Between 2017 and 2037, incident cases of bladder cancer will increase by over 40% in the US, Japan, and five major EU markets.
- Immunotherapy developers will seek label expansions in a variety of treatment settings to differentiate their products.
- Late-phase targeted therapies will look to address needs not met by immunotherapies.
Table of Contents
FORECAST: BLADDER CANCER (Published on 04 July 2017)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Bavencio (Avelumab)
Cyramza (Ramucirumab)
Erdafitinib
Imfinzi (Durvalumab)
Keytruda (Pembrolizumab)
Opdivo (Nivolumab)
Tecentriq (Atezolizumab)
Primary Research Methodology
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Bavencio (Avelumab)
Cyramza (Ramucirumab)
Erdafitinib
Imfinzi (Durvalumab)
Keytruda (Pembrolizumab)
Opdivo (Nivolumab)
Tecentriq (Atezolizumab)
Primary Research Methodology
TREATMENT: BLADDER CANCER (Published on 05 June 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends
EPIDEMIOLOGY: BLADDER CANCER (Published on 19 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Disease Background
Methodology
Forecast
Bibliography
MARKETED DRUGS: BLADDER CANCER (Published on 04 July 2017)
Overview
Executive Summary
Product Overview
Product Profile: Bavencio
Product Profile: Imfinzi
Product Profile: Keytruda
Product Profile: Opdivo
Product Profile: Tecentriq
Executive Summary
Product Overview
Product Profile: Bavencio
Product Profile: Imfinzi
Product Profile: Keytruda
Product Profile: Opdivo
Product Profile: Tecentriq
PIPELINE: BLADDER CANCER (Published on 04 July 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Clinical Trial Design
Key Pipeline Intravesical Therapies
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Erdafitinib
Executive Summary
Clinical Pipeline Overview
Clinical Trial Design
Key Pipeline Intravesical Therapies
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Erdafitinib
LIST OF FIGURES
Figure 1: Bladder cancer market value in the US, Japan, and five major EU markets, by country, 2016–25
Figure 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class, 2016–25
Figure 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016–25
Figure 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016–25
Figure 5: Patient-based forecast methodology for bladder cancer
Figure 6: Price sources and calculations, by country
Figure 7: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 8: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 9: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 10: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 11: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Distribution of bladder cancer patients across the US, Japan, and five major EU markets, by stage and country
Figure 15: Percentage of NMIBC patients who receive each type of treatment, by country
Figure 16: Top three intravesical therapies for NMIBC, by country
Figure 17: Percentage of MIBC patients who receive each type of treatment, by country
Figure 18: MIBC patients treated with cystectomy and systemic therapy who receive adjuvant chemotherapy, neoadjuvant chemotherapy, or both, by country
Figure 19: Top three regimens used in the neoadjuvant treatment of MIBC patients, by country
Figure 20: Top three regimens used in the adjuvant treatment of MIBC patients, by country
Figure 21: Percentage of Stage IV bladder cancer patients who receive each treatment type, by country
Figure 22: Top three regimens used in the first-line treatment of Stage IV bladder cancer patients, by country
Figure 23: Top three regimens used for second-line treatment of Stage IV bladder cancer patients, by country
Figure 24: Percentage of local relapse bladder cancer patients who receive each treatment type, by country
Figure 25: Top three regimens used for first-line treatment of local relapse bladder cancer, by country
Figure 26: Percentage of distant relapse bladder cancer patients who receive each treatment type, by country
Figure 27: Top three regimens used for first-line treatment of distant relapse bladder cancer, by country
Figure 28: Trends in incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017–37
Figure 29: Bavencio for urothelial bladder cancer – SWOT analysis
Figure 30: The authors drug assessment summary for Bavencio in urothelial bladder cancer
Figure 31: The authors drug assessment summary for Bavencio in urothelial bladder cancer
Figure 32: Imfinzi for urothelial bladder cancer – SWOT analysis
Figure 33: The authors drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 34: The authors drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 35: Keytruda for urothelial bladder cancer – SWOT analysis
Figure 36: The authors drug assessment summary for Keytruda in urothelial bladder cancer
Figure 37: The authors drug assessment summary for Keytruda in urothelial bladder cancer
Figure 38: Opdivo for urothelial bladder cancer – SWOT analysis
Figure 39: The authors drug assessment summary for Opdivo in urothelial bladder cancer
Figure 40: The authors drug assessment summary for Opdivo in urothelial bladder cancer
Figure 41: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 42: The authors drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 43: The authors drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 44: Erdafitinib for urothelial bladder cancer – SWOT analysis
Figure 45: The authors drug assessment summary for erdafitinib in urothelial bladder cancer
Figure 46: The authors drug assessment summary for erdafitinib in urothelial bladder cancer
Figure 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class, 2016–25
Figure 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016–25
Figure 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand, 2016–25
Figure 5: Patient-based forecast methodology for bladder cancer
Figure 6: Price sources and calculations, by country
Figure 7: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 8: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 9: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 10: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 11: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Figure 14: Distribution of bladder cancer patients across the US, Japan, and five major EU markets, by stage and country
Figure 15: Percentage of NMIBC patients who receive each type of treatment, by country
Figure 16: Top three intravesical therapies for NMIBC, by country
Figure 17: Percentage of MIBC patients who receive each type of treatment, by country
Figure 18: MIBC patients treated with cystectomy and systemic therapy who receive adjuvant chemotherapy, neoadjuvant chemotherapy, or both, by country
Figure 19: Top three regimens used in the neoadjuvant treatment of MIBC patients, by country
Figure 20: Top three regimens used in the adjuvant treatment of MIBC patients, by country
Figure 21: Percentage of Stage IV bladder cancer patients who receive each treatment type, by country
Figure 22: Top three regimens used in the first-line treatment of Stage IV bladder cancer patients, by country
Figure 23: Top three regimens used for second-line treatment of Stage IV bladder cancer patients, by country
Figure 24: Percentage of local relapse bladder cancer patients who receive each treatment type, by country
Figure 25: Top three regimens used for first-line treatment of local relapse bladder cancer, by country
Figure 26: Percentage of distant relapse bladder cancer patients who receive each treatment type, by country
Figure 27: Top three regimens used for first-line treatment of distant relapse bladder cancer, by country
Figure 28: Trends in incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017–37
Figure 29: Bavencio for urothelial bladder cancer – SWOT analysis
Figure 30: The authors drug assessment summary for Bavencio in urothelial bladder cancer
Figure 31: The authors drug assessment summary for Bavencio in urothelial bladder cancer
Figure 32: Imfinzi for urothelial bladder cancer – SWOT analysis
Figure 33: The authors drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 34: The authors drug assessment summary for Imfinzi in urothelial bladder cancer
Figure 35: Keytruda for urothelial bladder cancer – SWOT analysis
Figure 36: The authors drug assessment summary for Keytruda in urothelial bladder cancer
Figure 37: The authors drug assessment summary for Keytruda in urothelial bladder cancer
Figure 38: Opdivo for urothelial bladder cancer – SWOT analysis
Figure 39: The authors drug assessment summary for Opdivo in urothelial bladder cancer
Figure 40: The authors drug assessment summary for Opdivo in urothelial bladder cancer
Figure 41: Tecentriq for urothelial bladder cancer – SWOT analysis
Figure 42: The authors drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 43: The authors drug assessment summary for Tecentriq in urothelial bladder cancer
Figure 44: Erdafitinib for urothelial bladder cancer – SWOT analysis
Figure 45: The authors drug assessment summary for erdafitinib in urothelial bladder cancer
Figure 46: The authors drug assessment summary for erdafitinib in urothelial bladder cancer
LIST OF TABLES
Table 1: Bladder cancer market value in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2016–25
Table 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 5: Summary of drug classes and molecules in The authors bladder cancer forecast, 2016-25
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016–25
Table 8: Estimated launch dates of key pipeline products and marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016–25
Table 9: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Bavencio patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 11: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: Cyramza patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 13: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: Erdafitinib patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 15: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Imfinzi patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 17: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Keytruda patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 19: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 20: Opdivo patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 21: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: Tecentriq patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 23: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
Table 24: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
Table 25: Bladder cancer five-year survival rates in the US, by stage at diagnosis
Table 26: TNM classification of bladder cancer, by stage at diagnosis
Table 27: Leading treatments for bladder cancer
Table 28: T staging within the TNM classification of bladder cancer
Table 29: International Classification of Diseases topography codes for bladder cancer
Table 30: Cancer registry databases used as a source of bladder cancer incidence data, by country
Table 31: Sources of survival data used to estimate bladder cancer prevalence, by country
Table 32: Validation of forecast estimates against benchmark estimates, by country
Table 33: Incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017–37
Table 34: Key marketed products for bladder cancer
Table 35: Bavencio drug profile
Table 36: Bavencio pivotal trial data in urothelial bladder cancer
Table 37: Bavencio ongoing late-phase trials in urothelial bladder cancer
Table 38: Imfinzi drug profile
Table 39: Imfinzi pivotal trial data in urothelial bladder cancer
Table 40: Imfinzi ongoing late-phase trials in urothelial bladder cancer
Table 41: Keytruda drug profile
Table 42: Keytruda pivotal trial data in urothelial bladder cancer
Table 43: Keytruda ongoing late-phase trials in urothelial bladder cancer
Table 44: Keytruda early-phase data in urothelial bladder cancer
Table 45: Opdivo drug profile
Table 46: Opdivo pivotal trial data in urothelial bladder cancer
Table 47: Opdivo ongoing late-phase trials in urothelial bladder cancer
Table 48: Tecentriq drug profile
Table 49: Tecentriq pivotal trial data in urothelial bladder cancer
Table 50: Tecentriq ongoing late-phase trials in urothelial bladder cancer
Table 51: Late-phase pipeline products in development for urothelial bladder cancer
Table 52: BC-819 drug profile
Table 53: Instiladrin drug profile
Table 54: Vicinium drug profile
Table 55: Erdafitinib drug profile
Table 56: Key erdafitinib Phase II trial in urothelial bladder cancer
Table 57: Erdafitinib early-phase data in urothelial bladder cancer
Table 2: Bladder cancer market value in the US, Japan, and five major EU markets, by drug class ($m), 2016–25
Table 3: Sales of PD-1/PD-L1 inhibitors for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 4: Sales of Cyramza and erdafitinib for bladder cancer in the US, Japan, and five major EU markets, by brand ($m), 2016–25
Table 5: Summary of drug classes and molecules in The authors bladder cancer forecast, 2016-25
Table 6: Exchange rates used for calculating prices
Table 7: Patent expiry dates for key marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016–25
Table 8: Estimated launch dates of key pipeline products and marketed brands in bladder cancer in the US, Japan, and five major EU markets, 2016–25
Table 9: Bavencio sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Bavencio patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 11: Cyramza sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 12: Cyramza patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 13: Erdafitinib sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 14: Erdafitinib patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 15: Imfinzi sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 16: Imfinzi patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 17: Keytruda sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 18: Keytruda patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 19: Opdivo sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 20: Opdivo patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 21: Tecentriq sales for bladder cancer in the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 22: Tecentriq patient numbers for bladder cancer in the US, Japan, and five major EU markets, by country, 2016–25
Table 23: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
Table 24: Medical oncologists and urologists surveyed for the urothelial bladder cancer primary research study, 2016
Table 25: Bladder cancer five-year survival rates in the US, by stage at diagnosis
Table 26: TNM classification of bladder cancer, by stage at diagnosis
Table 27: Leading treatments for bladder cancer
Table 28: T staging within the TNM classification of bladder cancer
Table 29: International Classification of Diseases topography codes for bladder cancer
Table 30: Cancer registry databases used as a source of bladder cancer incidence data, by country
Table 31: Sources of survival data used to estimate bladder cancer prevalence, by country
Table 32: Validation of forecast estimates against benchmark estimates, by country
Table 33: Incident cases of bladder cancer in the US, Japan, and five major EU markets, by country, 2017–37
Table 34: Key marketed products for bladder cancer
Table 35: Bavencio drug profile
Table 36: Bavencio pivotal trial data in urothelial bladder cancer
Table 37: Bavencio ongoing late-phase trials in urothelial bladder cancer
Table 38: Imfinzi drug profile
Table 39: Imfinzi pivotal trial data in urothelial bladder cancer
Table 40: Imfinzi ongoing late-phase trials in urothelial bladder cancer
Table 41: Keytruda drug profile
Table 42: Keytruda pivotal trial data in urothelial bladder cancer
Table 43: Keytruda ongoing late-phase trials in urothelial bladder cancer
Table 44: Keytruda early-phase data in urothelial bladder cancer
Table 45: Opdivo drug profile
Table 46: Opdivo pivotal trial data in urothelial bladder cancer
Table 47: Opdivo ongoing late-phase trials in urothelial bladder cancer
Table 48: Tecentriq drug profile
Table 49: Tecentriq pivotal trial data in urothelial bladder cancer
Table 50: Tecentriq ongoing late-phase trials in urothelial bladder cancer
Table 51: Late-phase pipeline products in development for urothelial bladder cancer
Table 52: BC-819 drug profile
Table 53: Instiladrin drug profile
Table 54: Vicinium drug profile
Table 55: Erdafitinib drug profile
Table 56: Key erdafitinib Phase II trial in urothelial bladder cancer
Table 57: Erdafitinib early-phase data in urothelial bladder cancer
